Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).

Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).

SYN002, an emerging biotech company developing breakthrough drugs for the treatment of chronic viral infections, has completed a Series A fundraise of EUR 29.8 million (DKK 222 million / USD 31.8 million) accelerating its development plans towards significant clinical milestones.

Synklino, which develops an innovative and groundbreaking drug for the treatment of cytomegalovirus (CMV) infections in transplant recipients, announces today that the company has completed a financing round of DKK 106 million/Eur 14 million corresponding to three times the original target.